Company Overview: BLUE

Upcoming Projects (BLUE)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (BLUE)

Discussing BLUE’s new SCD results from ASH 2018 and the sickle cell treatment landscape.
Tickers: BLUE, GBT
Executed On: Dec 14, 2018 at 10:00 AM EST
A 4th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jul 11, 2018 at 04:00 PM EDT
A 3rd View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jul 02, 2018 at 03:00 PM EDT
A 2nd Look: Discussing this week's Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jun 29, 2018 at 01:00 PM EDT
FLASH CALL: Discussing this morning's Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jun 27, 2018 at 04:00 PM EDT
Biotech readout: Taking stock halfway through the year
Tickers: STAT, XLRN, ALNY, CELG, BLUE, SGMO
Executed On: Jun 12, 2018 at 01:00 PM EDT
Included with Membership
Discussing the latest GBT Sickle Cell Trial for Voxelotor (Previously GBT440) and its market potential
Tickers: GBT, BLUE
Executed On: Apr 25, 2018 at 01:00 PM EDT
SPONSORED BY LONCAR INDEX - Third Annual Key Takeaways in CAR-T from ASH 2017
Tickers: GILD, JUNO, CLLS, CELG, NVS, BLUE
Executed On: Dec 21, 2017 at 02:00 PM EST
Free Project
Sponsored Project by the THE LONCAR INDEX: 2016 ASH Recap Highlighting the Latest Data In the CAR-T Space
Tickers: NVS, KITE, JUNO, CELG, BLUE
Executed On: Dec 15, 2016 at 03:00 PM EST
Free Project
Analyzing the Previously Released Data on Mast Therapeutics' (MSTX) Vepoloxamer in Sickle Cell Disease and What It Can Tell Us About The Drug's Chance For Success In The Phase 3 EPIC Trial (Interview 1 of 3)
Tickers: MSTX, PFE, BLUE
Executed On: May 03, 2016 at 10:30 AM EDT
Leigh Drogen, Founder of Estimize, joins Joe McCann of Slingshot Insights to talk Biotech stocks, the market, and his latest creation ForceRank. ForceRank is being called "Fanduel For Stocks" and is already live for real money.
Tickers: FORCERANK, BIIB, CELG, ALNY, BLUE, KITE, estimize
Executed On: Apr 07, 2016 at 03:00 PM EDT
Free Project

Upcoming & Overdue Catalysts (BLUE)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (BLUE)

Bluebird Bio's(BLUE) Phase 3 data of LentiGlobin - HGB-212 Northstar-3 in TDT and the β0/β0genotype to be presented at EHA
Ticker: BLUE
Occurred on: Jun 14, 2019
Bluebird Bio (BLUE) to complete Phase 2/3 Study of Hematopoietic Stem Cells Transduced with Lenti-D Lentiviral Vector for the treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD) in second half of 2018
Ticker: BLUE
Occurred on: Sep 05, 2018
Bluebird Bio (BLUE) to finish Phase 1/2 study of LentiGlobin® BB305 in Beta-Thalassemia Major Subjects in September 2017
Ticker: BLUE
Occurred on: Dec 10, 2017
Bluebird Bio (BLUE) to complete Phase 1/2 study of LentiGlobin BB305 to subjects with beta-thalassemia major or severe sickle cell disease in December 2017
Ticker: BLUE
Occurred on: Dec 10, 2017
Phase 1/2 trial updated data of LentiGlobin for β-Thalassemia and Sickle Disease expected at ASH December 2016
Ticker: BLUE
Occurred on: Dec 05, 2016
BlueBird Bio's (BLUE) LentiGlobin for Transfusion-Dependent Beta Thalassemia Granted PRIME Status by EMA
Ticker: BLUE
Occurred on: Sep 21, 2016
FDA has removed the clinical hold on the Phase II clinical trial of JCAR015 (known as the “ROCKET” trial) in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL)
Tickers: JUNO, CLLS, KITE, BLUE, ZIOP
Occurred on: Jul 12, 2016
Bluebird Bio (BLUE) to present interim data from Starbeam Study of Lenti-D for its effectiveness in treating cerebral adrenoleukodystrophy at the American Academy of Neurology (AAN) 2016
Ticker: BLUE
Occurred on: Apr 20, 2016
Bluebird Bio (BLUE) will present data from the ongoing Phase 2/3 Starbeam Study (ALD-102) for the treatment of cerebral adrenoleukodystrophy (CALD) at the American Academy of Neurology (AAN) 2016 Annual Meeting
Ticker: BLUE
Occurred on: Apr 20, 2016
Bluebird Bio (BLUE) CFO to resign, replaced by COO
Ticker: BLUE
Occurred on: Mar 18, 2016
Leukemia Research presented at American Association for the Advancement of Science (AAAS) leads to boost for CAR-T developers
Tickers: BLUE, KITE, CLLS, ZIOP, JUNO, BLCM, CYAD, ADAP
Occurred on: Feb 16, 2016

Strategic Initiatives (BLUE)

Bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
Ticker: BLUE
Announcement Date: Dec 07, 2017

BLUE Overview